Gilead Drug Delays Progression of Common Breast Cancers
- Treated patients show trend toward improved overall survival
- Antiviral drugmaker betting on expansion into cancer treatment
This article is for subscribers only.
Gilead Sciences Inc.’s drug Trodelvy slowed progression of a common type of breast cancer in early results from a study that could help expand use of the therapy.
The 543-patient study hit its main goal in treatment of spreading breast cancers bearing hormone receptors, proteins involved in cell growth that are often targeted by therapies. The interim analysis also showed a trend toward improvement in overall survival among patients treated with the drug, a secondary goal of the trial, according to a company statement.